Posted by Michael Wonder on 17 Oct 2016
FDA approves Genentech’s Lucentis (ranibizumab injection) pre-filled syringe
14 October 2016 - First anti-VEGF pre-filled syringe FDA approved to treat people with wet age-related macular degeneration and people with macular oedema after retinal vein occlusion.
Genentech today announced that the U.S. FDA approved the Lucentis (ranibizumab injection) 0.5 mg pre-filled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related macular degeneration and macular oedema after retinal vein occlusion.
The Lucentis PFS is the first syringe pre-filled with an anti-VEGF medicine FDA-approved to treat two eye conditions.
